Trial Profile
The effect of omeprazole on the pharmacokinetics of dasatinib (BMS-354825) in healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Dec 2009
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Omeprazole
- Indications Breast cancer; Chronic myeloid leukaemia; Colorectal cancer; Duodenal ulcer; Dyspepsia; Gastric ulcer; Gastro-oesophageal reflux; Helicobacter infections; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Peptic ulcer; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Zollinger-Ellison syndrome
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 14 Jul 2008 Actual patient number (49) added as reported by ClinicalTrials.gov.
- 14 Jul 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 May 2008 Status changed from initiated to recruiting.